Multiple Sclerosis

The ongoing PERSEUS trial explores tolebrutinib's potential as a treatment for primary progressive multiple sclerosis, with results anticipated soon.

Engaging care partners in multiple sclerosis treatment enhances patient outcomes and supports their well-being, fostering healthier care partnerships.

New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple sclerosis.

The 39th CMSC Annual Meeting is set to be held May 28-31, 2025, in Phoenix, Arizona. The International Journal of MS Care has published the abstracts.

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. [WATCH TIME: 4 minutes]

A recent large cohort analysis of global MS registry data reported that the incidence and persistence of progression independent of relapse activity varied widely depending on how it was defined.

Experts discussed how aging impacts multiple sclerosis management, treatment decisions, and overall patient health. [WATCH TIME: 5 minutes]

Experts discussed the current and future applications of AI and machine learning in multiple sclerosis research and clinical care, highlighting both opportunities and limitations. [WATCH TIME: 9 minutes]

Experts discussed the promise and uncertainty surrounding BTK inhibitors and CAR T-cell therapy in addressing progressive multiple sclerosis. [WATCH TIME: 8 minutes]

Evan L. Smith, PhD, assistant professor of Physical Medicine & Rehabilitation at University of Michigan, discussed how emotional wellbeing, motivation, and evidence-based therapies can significantly influence outcomes in MS.

The award ceremony is supported by Viatris and will take place on Thursday, May 29, 2025, at the Phoenix Convention Center in Phoenix, Arizona, during the 2025 CMSC Annual Meeting.

Jack P. Antel, MD, professor of neurology and neurosurgery at McGill University, reflected on key advances in neuroimmune research and their implications for understanding and treating MS.

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements.

In a large Swedish MS cohort, higher combined intake of lean and oily fish was linked to significantly reduced risks of confirmed disability worsening and EDSS progression, independent of lifestyle factors.

The phase 2 trial, spanning across 4 sites in the United States, evaluates dose-dependent safety, tolerability, and microglial modulation of foralumab in a cohort of nonactive secondary progressive multiple sclerosis.

The executive vice president of research at the National MS Society talked about how the award continues to honor transformative multiple sclerosis research and inspire the next generation of investigators. [WATCH TIME: 5 minutes]

The director of NYU Langone's Multiple Sclerosis Comprehensive Care Center discussed the importance of early, high-efficacy treatment for pediatric MS. [WATCH TIME: 3 minutes]

Experts discussed recent advancements in diagnostic criteria, imaging techniques, and the evolving understanding of multiple sclerosis subtypes and treatment responses. [WATCH TIME: 10 minutes]

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]

Long-term data from a phase 2 study extension suggest that frexalimab, a CD40L inhibitor, maintains disease control and is well-tolerated in relapsing multiple sclerosis, reinforcing its potential as a next-generation treatment.

The company's phase 3 MUSETTE trial reported that an increased ocrelizumab dose did not further slow disability progression but reinforced the efficacy of the approved 600 mg dose.

The assistant professor in the department of neurology at Mount Sinai discussed distinguishing cognitive impairment in MS from AD emphasizing orientation as a key differentiator. [WATCH TIME: 5 minutes]

The professor of neurology at University of Colorado School of Medicine talked about the challenges of telehealth and device-based data collection in clinical practice. [WATCH TIME: 4 minutes]

The professor of neurological sciences at the University of Vermont discussed the work of the MS Differential Diagnosis Consortium, highlighting efforts to refine MS differential diagnosis and improve clinical accuracy. [WATCH TIME: 8 minutes]

The medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed findings from phase 3 trials suggesting that baseline PRLs can predict disability accumulation and may serve as biomarkers for treatment response to tolebrutinib. [WATCH TIME: 6 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 14, 2025.

Kathleen Costello discusses her new role as interim CEO of the CMSC. She has the support of Jeff Wilken, CMSC president, and Tina Trott, CMSC director.

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

The associate researcher at the University of California, San Francisco discussed a refined EAE model that could better replicate MS pathology, enabling deeper insights into demyelination, neuronal loss, and remyelination. [WATCH TIME: 6 minutes]